GlobeNewswire
Nasus Pharma to Participate in Upcoming Investor Conferences
📊
AI Sentiment
Positive
6/10
- Home
- NSRX
as of 02-25-2026 3:32pm EST
$5.06
$0.20
-3.79%
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
| Founded: | 2019 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 53.5M | IPO Year: | N/A |
| Target Price: | $20.50 | AVG Volume (30 days): | 2.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $4.90 - $9.99 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Latest Nasus Pharma Ltd. Ordinary Shares News
NSRX Breaking Stock News: Dive into NSRX Ticker-Specific Updates for Smart Investing
Compare NSRX vs Leading Stocks
See how NSRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NSRX Nasus Pharma Ltd. Ordinary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.